2026 Q3 -tulosraportti
Vain PDF
105 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,50%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 11.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sittenChemoMetec + Hamilton – XM30 as an integration case I have noted Hamilton's webinar on August 26th, where ChemoMetec's Director of Product Management participates. Hamilton is a key player in laboratory automation with their easyBlood STAR/STARlet platform, which handles blood fractionation and pre-analytical workflows. The interesting thing is not the webinar itself, but the possible technological link to ChemoMetec's XM30. XM30 is designed to be directly integrated into automated production and analysis flows, where samples are delivered via robotic arm, and cell counting/quality measurement occurs fully automatically. This makes it ideal as a downstream module in precisely the type of systems Hamilton builds. There is no indication yet of a formal commercial collaboration, but several data points are worth noting: CHEM and Hamilton have previously appeared together at XcytoMatic User Network Days Hamilton's pre-analytics product manager is involved in the webinar series CHEM is now directly participating in Hamilton's event XM30 is explicitly developed for integration into automated workflows This fits into a broader strategy where CHEM is trying to position XM30 as a module in larger bioprocess and automation platforms. This is also supported by the recent Roche collaboration agreement, where XM30 is linked to Cedex Bio Analyzer with joint development, validation, and go-to-market. It is a clear example of the same integration strategy. In this light, the Hamilton webinar could be interesting if there are concrete signals about: workflow-integration validation or customer cases or early commercial implementations I have signed up myself to follow along. Conclusion: It could be a non-event – but also an early signal about where XM30 is heading into automated laboratory ecosystems.
·13.8.I have a feeling I unfortunately missed the run, don't know how much I believe in a break 500 within a short time, what do you say? Is it too late to jump on?I believe Chemo can become something much bigger than it is today. XM40, for example, is not exclusively designed for cell therapy, but can be used in all biological production. That is, everywhere cells are cultured on a large scale, whether for cancer treatments, blood-thinning medication, insulin, vaccines or other biological drugs… It's a huge market, 10-20x larger than cell therapy alone. Beckman Coulter dominates this market today with its instrument, but one can argue that Chemo has a technologically superior solution, but has hitherto lacked entry into this market, because Beckman heavily occupies the installed customer base. So perhaps this is where the Roche agreement becomes interesting. For over a decade, Roche sold the standard instrument for precisely this bioprocessing market, and now they are phasing it out. This could be the entry ticket to a market Chemo would not have been able to open up for on its own. What else might come out of a strategic collaboration with Roche over the next 5 to 15 years is hard to say, but such collaborations typically start in one place and end in a completely different one. Roche is one of the world's largest diagnostics companies and Chemo is a small Danish company with superior technology. The combination of Roche's large sales network and customer knowledge with Chemo's instruments and competencies can open doors they would never have reached alone, as I interpret it.
·10.8.It will go up and down but sure it hits 500 before January, believe the top can be as high as 550 maybe more good news or results can push it further
I couldn't understand why the value of my portfolio had increased. I had just forgotten that I had Chem. One of the good surprises. How will one be able to see a concrete sales effect from the Roche collaboration?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
Vain PDF
105 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,50%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenChemoMetec + Hamilton – XM30 as an integration case I have noted Hamilton's webinar on August 26th, where ChemoMetec's Director of Product Management participates. Hamilton is a key player in laboratory automation with their easyBlood STAR/STARlet platform, which handles blood fractionation and pre-analytical workflows. The interesting thing is not the webinar itself, but the possible technological link to ChemoMetec's XM30. XM30 is designed to be directly integrated into automated production and analysis flows, where samples are delivered via robotic arm, and cell counting/quality measurement occurs fully automatically. This makes it ideal as a downstream module in precisely the type of systems Hamilton builds. There is no indication yet of a formal commercial collaboration, but several data points are worth noting: CHEM and Hamilton have previously appeared together at XcytoMatic User Network Days Hamilton's pre-analytics product manager is involved in the webinar series CHEM is now directly participating in Hamilton's event XM30 is explicitly developed for integration into automated workflows This fits into a broader strategy where CHEM is trying to position XM30 as a module in larger bioprocess and automation platforms. This is also supported by the recent Roche collaboration agreement, where XM30 is linked to Cedex Bio Analyzer with joint development, validation, and go-to-market. It is a clear example of the same integration strategy. In this light, the Hamilton webinar could be interesting if there are concrete signals about: workflow-integration validation or customer cases or early commercial implementations I have signed up myself to follow along. Conclusion: It could be a non-event – but also an early signal about where XM30 is heading into automated laboratory ecosystems.
- ·13.8.I have a feeling I unfortunately missed the run, don't know how much I believe in a break 500 within a short time, what do you say? Is it too late to jump on?I believe Chemo can become something much bigger than it is today. XM40, for example, is not exclusively designed for cell therapy, but can be used in all biological production. That is, everywhere cells are cultured on a large scale, whether for cancer treatments, blood-thinning medication, insulin, vaccines or other biological drugs… It's a huge market, 10-20x larger than cell therapy alone. Beckman Coulter dominates this market today with its instrument, but one can argue that Chemo has a technologically superior solution, but has hitherto lacked entry into this market, because Beckman heavily occupies the installed customer base. So perhaps this is where the Roche agreement becomes interesting. For over a decade, Roche sold the standard instrument for precisely this bioprocessing market, and now they are phasing it out. This could be the entry ticket to a market Chemo would not have been able to open up for on its own. What else might come out of a strategic collaboration with Roche over the next 5 to 15 years is hard to say, but such collaborations typically start in one place and end in a completely different one. Roche is one of the world's largest diagnostics companies and Chemo is a small Danish company with superior technology. The combination of Roche's large sales network and customer knowledge with Chemo's instruments and competencies can open doors they would never have reached alone, as I interpret it.
- ·10.8.It will go up and down but sure it hits 500 before January, believe the top can be as high as 550 maybe more good news or results can push it furtherI couldn't understand why the value of my portfolio had increased. I had just forgotten that I had Chem. One of the good surprises. How will one be able to see a concrete sales effect from the Roche collaboration?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 11.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
2026 Q3 -tulosraportti
Vain PDF
105 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 11.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
7,00 DKK/osake
Viimeisin osinko
1,50%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenChemoMetec + Hamilton – XM30 as an integration case I have noted Hamilton's webinar on August 26th, where ChemoMetec's Director of Product Management participates. Hamilton is a key player in laboratory automation with their easyBlood STAR/STARlet platform, which handles blood fractionation and pre-analytical workflows. The interesting thing is not the webinar itself, but the possible technological link to ChemoMetec's XM30. XM30 is designed to be directly integrated into automated production and analysis flows, where samples are delivered via robotic arm, and cell counting/quality measurement occurs fully automatically. This makes it ideal as a downstream module in precisely the type of systems Hamilton builds. There is no indication yet of a formal commercial collaboration, but several data points are worth noting: CHEM and Hamilton have previously appeared together at XcytoMatic User Network Days Hamilton's pre-analytics product manager is involved in the webinar series CHEM is now directly participating in Hamilton's event XM30 is explicitly developed for integration into automated workflows This fits into a broader strategy where CHEM is trying to position XM30 as a module in larger bioprocess and automation platforms. This is also supported by the recent Roche collaboration agreement, where XM30 is linked to Cedex Bio Analyzer with joint development, validation, and go-to-market. It is a clear example of the same integration strategy. In this light, the Hamilton webinar could be interesting if there are concrete signals about: workflow-integration validation or customer cases or early commercial implementations I have signed up myself to follow along. Conclusion: It could be a non-event – but also an early signal about where XM30 is heading into automated laboratory ecosystems.
- ·13.8.I have a feeling I unfortunately missed the run, don't know how much I believe in a break 500 within a short time, what do you say? Is it too late to jump on?I believe Chemo can become something much bigger than it is today. XM40, for example, is not exclusively designed for cell therapy, but can be used in all biological production. That is, everywhere cells are cultured on a large scale, whether for cancer treatments, blood-thinning medication, insulin, vaccines or other biological drugs… It's a huge market, 10-20x larger than cell therapy alone. Beckman Coulter dominates this market today with its instrument, but one can argue that Chemo has a technologically superior solution, but has hitherto lacked entry into this market, because Beckman heavily occupies the installed customer base. So perhaps this is where the Roche agreement becomes interesting. For over a decade, Roche sold the standard instrument for precisely this bioprocessing market, and now they are phasing it out. This could be the entry ticket to a market Chemo would not have been able to open up for on its own. What else might come out of a strategic collaboration with Roche over the next 5 to 15 years is hard to say, but such collaborations typically start in one place and end in a completely different one. Roche is one of the world's largest diagnostics companies and Chemo is a small Danish company with superior technology. The combination of Roche's large sales network and customer knowledge with Chemo's instruments and competencies can open doors they would never have reached alone, as I interpret it.
- ·10.8.It will go up and down but sure it hits 500 before January, believe the top can be as high as 550 maybe more good news or results can push it furtherI couldn't understand why the value of my portfolio had increased. I had just forgotten that I had Chem. One of the good surprises. How will one be able to see a concrete sales effect from the Roche collaboration?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt